As mentioned above, AF patients with high levels of HSPB1 at baseline and who were treated for 3 months with the HSP-inducing compound L-glutamine showed significant reduction in serum HSPB1 levels accompanied with normalization of metabolite levels compared with patients with low HSP levels at baseline. The gene discussed is HSP90B2P; the disease is atrial fibrillation.